Edgewise Therapeutics Inc. Common Stock vs JFrog Ltd. Ordinary Shares — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.04 (market cap $3.94B), while JFrog Ltd. Ordinary Shares trades at $91 (market cap $12.24B). The key difference: JFrog Ltd. Ordinary Shares is far larger — about 3.1× Edgewise Therapeutics Inc. Common Stock's market cap, and JFrog Ltd. Ordinary Shares is trading nearer its 52-week high, Edgewise Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and JFrog Ltd. Ordinary Shares for 5 Days on average.
| EWTX | FROG | |
|---|---|---|
Market Cap | $3.94B | $12.24B |
Volume | 810,104 | 1,786,951 |
Sector | Health | Technology |
52-Week High | $48.35 | $104.03 |
52-Week Low | $14.89 | $34.75 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $3.48B | $11.43B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JFrog (FROG) trades at $99.28, up 0.26% on the day, showing strong technical momentum with a bullish moving average signal and trading near pivot point resistance at $99. The company has beaten earnings expectations for three consecutive quarters, with Q3 2026 results pending, while maintaining robust revenue growth projections from $532M in 2025 to $600M in 2026. Recent product announcements at swampUP 2026 focused on AI-era software supply chain security enhancements.
Wall Street maintains strong bullish sentiment with 87.5% buy ratings and a $110.25 consensus price target, representing 11% upside potential. However, negative profitability metrics and insider selling activity present near-term headwinds. The stock's elevated P/S ratio of 19.77 requires continued execution on growth targets to justify valuation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →JFrog provides software supply chain tools that help developers manage, secure, and distribute software packages. Its platform is used across development and deployment workflows.
Read more on FROG →